Allelix Biopharmaceuticals Inc.

Resolution Pharmaceuticals Inc.

Resolution Pharmaceutical Inc.

Resolutions Pharmaceuticals, Inc.

Robert A Kirby

Ashok Tehim

Alfred Pollak

Jian-Min Fu

Robert Dunn-Dufault

Robert Dufault

Alfred Pollack

Radionuclide chelating compounds are provided for conjugation to targetting molecules such as proteins, peptides or antibodies. The resulting labelled targetting molecules may be used in diagnosis and therapy.

Hydrazino-type N.sub.2 S.sub.2 radionuclide chelating compounds

Described herein are D4 receptor-selective compounds of the general formula: ##STR1## wherein: A and B are independently selected, optionally substituted, saturated or unsaturated 5- or 6-membered, homo- or heterocyclic rings;

Benzyl-substituted compounds having dopamine receptor affinity

Radionuclide chelating compounds are provided for conjugation to targeting molecules such as proteins, peptides or antibodies. The resulting labeled targeting molecules may be used in diagnosis and therapy.

Hydrazino-type radionuclide chelators having an N.sub.3 S configuration

Radionuclide chelating compounds are provided for conjugation to targetting molecules such as proteins, peptides or antibodies. The resulting labelled targetting molecules may be used in diagnosis and therapy. ##STR1##

Growing community of inventors

Acton, Canada

Robert A Kirby